Dr. Harlan Krumholz is a cardiologist, leading research scientist and Professor of Medicine at Yale school of medicine where he has been on the faculty since 1992. A pioneer in the development of the field of outcomes research, his groundbreaking contributions to science have directly led to improvements in healthcare outcomes for patients and populations. He is the founder and Director of the Yale New Haven Hospital Center for outcomes research and evaluation. He has published over 1000 articles and is one of the most prolific and highly cited researchers in the world.
Kindred @ Hugohealth.com is a site to help collect and store medical records and connect with others. In addition, he discussed the Yale LISTEN study which aims to study subgroups of people identified with similar characteristics.
If you are interested in the Yale LISTEN study, please see the FAQ here:
This is such a necessary service for a multitude of ppl. I am so happy to see the creation of a specific medical
Support system that partners with the affected persons from this terrible situation. Best of luck Dr. People helping people. It’s exactly what is needed.
One reported adverse effect from Covid vaccination is hearing loss. But the video has no closed captioning, despite mature closed caption generation technology now being available.
Hi Robert, thanks for the feedback. It would be nice if we had the manpower to tackle ‘nice to have’ issues. One of the additional difficulties that we face is that videos often get de-platformed off Youtube, which has an auto-captioning feature.
I have experienced loss of taste and smell – approximately 50 to 60%. Yale researchers discovered that COVID-19 patients who were treated with camostat mesylate did not suffer loss of taste. Please see the following publication from Yale Med Sch:
Please see an article below published by Yale Med Sch.
“A Way To Prevent Loss of Smell and Taste From COVID-19?
BY CARRIE MACMILLAN March 28, 2022
Yale researchers share surprising clinical trial results.
Dr. Vinetz recruited several colleagues to collaborate, including Anne Spichler Moffarah, MD, PhD, an infectious diseases specialist, and Gary Desir, MD, chair of the Department of Internal Medicine. Geoffrey Chupp, MD, director of the Yale Center for Asthma and Airways Disease, ran the clinical trial.
The Phase II randomized trial enrolled 70 participants who tested positive for COVID-19 within three days of starting the study. Participants took the medicine four times a day for seven days.
Although the trial was stopped once it was clear that the main objective of reducing viral load was not occurring, the researchers think the surprise findings about loss of smell and taste warrant additional study. Please see the below taken from a website
“My daughter had COVID a year ago and she still has trouble smelling and tasting things,” says Dr. Desir. “This drug seems to be able to modulate that loss of smell and taste. It has very few side effects and has been studied extensively. This could be the type of treatment that is given to someone with COVID at the onset of the infection.”
If the drug were to be approved for this purpose, the doctors believe it could be a game-changer. “It wouldn’t be an expensive medication. Our idea was that everyone would take it if they were diagnosed because it’s hard to predict who will lose their sense of smell or taste, and it’s better to prevent it than to wait for it to happen,” Dr. Desir says.
Whether camostat mesylate could help restore sense of taste or smell in someone who has lost it is unknown, he adds. “More studies would help us with that,” Dr. Chupp says.”
Are you aware of any new research on whether or not camostat mesylate is being studied to see if it can restore loss of taste? Approximately 1 million COVID-19 patients have lost taste.
camostat mesylate is approved in Japan for treatment of chronic pancreatitis and also goes by the name Forban; Fobanil; Forban mesilate and Derazantin. It is a protese Inhibitor for COVID-2.